Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95070 | 0.92 | CA2 (0.48) | CA2HCRTR1HCRTR2KMT2AMEN1 | |
| SCHEMBL94320 | 0.88 | CA2 (0.46) | CA2HCRTR1HCRTR2KMT2AMEN1 | |
| SCHEMBL13598464 | 0.86 | CA2 (0.47) | CA2KMT2AMEN1PTPN1ALDH1A1 | |
| SCHEMBL94559 | 0.83 | CA2 (0.48) | CA2HCRTR1HCRTR2PTPN1SIRT2 | |
| SCHEMBL13598471 | 0.83 | CA2 (0.42) | CA2HCRTR1HCRTR2KMT2AMEN1 | |
| SCHEMBL13598468 | 0.82 | CA2 (0.49) | CA2KMT2AMEN1PTPN1ALDH1A1 | |
| SCHEMBL94741 | 0.82 | CA2 (0.52) | CA2KMT2AMEN1PTPN1ALDH1A1 | |
| SCHEMBL95126 | 0.81 | CA2 (0.51) | CA2PTPN1 | |
| SCHEMBL13598466 | 0.81 | CA2 (0.51) | CA2PTPN1 | |
| SCHEMBL98176 | 0.81 | ABCB1 (0.43) | CA2KMT2APTPN1MCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | CA2 823/4885HCRTR1 2814/4885HCRTR2 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.